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1. Introduction 
Melanomas occur in 95% of cases as skin cancer (1.5-7% of all skin cancers) and only 5% in 
non-skin locations, especially the eye. The incidence has doubled every 10-20 years since the 
mid 20th century, but the mortality has not increased in the same proportion. Mortality has 
increased at a slower rate, thus showing that the higher incidence is mainly at the expenses 
of early lesions leading to early diagnosis and the application of curative surgical treatment. 
Globocan’s data from 2008 shows an incidence of 199.627 cases and a mortality of 46.372 (M: 
101.807/25.860 y W: 97.820/20512), when in 2002 the incidente was 160.000 (M:F sex ratio, 
0.97) and the mortality 41.000 (M:F sex ratio, 1.2) The majority of melanomas originate in 
existing nevi, only 30% are new lesions. Radial or spreading growth initially appears 
(malignant lentingo melanoma, superficial acral lentiginous melanoma) followed by vertical 
growth that involves lymphatic colonisation. Nodular melanoma only presents vertical 
growth, without any previous radial growth phase and this is why it has a worse prognosis. 
The Clark levels of invasion (I, II, III, IV and V) and Breslow's tumour thickness 
measurements (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0 mm), are based on the growth depth of 
histopathological studies and enable evaluating the prognosis and estimating the risk after 
surgery of the primary tumour (Dyson et al.2005). They indicate the risk of metastasis and 
are the bases and foundations of studies of tumour extension and classification.  
One important step is the study of the sentinel lymph node, which enables precise 
classification of lymph node affectations. This has good prognosis value and influences 
making later therapeutic decisions such as the use of high dose adjuvant interferon. 
Furthermore, in cases where these nodes are positive, it indicates the advantages of early 
lymphadenectomy. Its indication is for stages I-II of the AJCC, which is without evidence of 
regional or distant lymph node metastases that may include ultrasonography (Saiag et al. 
2005). The Breslow degree of millimetric invasion informs about the risk of hidden 
metastasis at a lymph node and distal level. If this degree of invasion is less than 1 mm, the 
positivity of the sentinel lymph node is only 0-5% and the cure rates by surgery are 98%. 
This means that in this group the indication of performing the sentinel lymph node 
technique is not logical because of its low indicative value. In patients with a degree of 
invasion between 1 and 4 mm (T2, T3) the positivity ranges from 1 to 14% in T2 and from 11 
to 34% in T3. This is why the sentinel lymph node technique would be very important in 
this group because of its prognostic and therapeutic repercussions. 
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In patients with a degree of invasion of more than 4 mm (T4), the risk of regional micro-
metastasis is very high, between 20-65%, as is that of distant micro-metastasis (>60%). This 
means that the sentinel lymph node technique would be less informative regarding 
palliative lymphadenectomy and the indication of treatment with high dose interferon. This 
procedure would be indicated from the outset, as the patients are high risk. Nevertheless, it 
would enable to adequate classification and this would be valuable when planning future 
clinical trials with more homogeneous groups of patients. (Table 1) (Moreno-Nogueira 
2008). 
 
 
1.- Tumour thickness of more than 1 mm. 
2.- Clark level higher than III. 
3.- Ulceration. 
4.- Histological signs of regression. 
 
Table 1. Histological criteria indicating the sentinel lymph node 
A histopathological study of the primary lesion and complementary examinations are the 
basis of the stage classification as a step prior to planning therapy following surgery. The 
AJCC/UICC classification of 2001 has evident differences compared to that of 1997. It 
simplifies the Breslow scale to 1, 2 and 4 mm and consider the presence of ulceration. It 
adequately classifies lymph node affectation and, in the metastatic phase, distinguishes 
types of metastasis and the prognosis value of high LDH levels. This disease classification 
finally includes assessment of the sentinel lymph node. All this enables identification of the 
different stages as well as different risk groups, an important aspect for deciding 
complementary treatments (Balch et al. 2001). 
Patients with stages I and II have no distant lymph node metastases and survival rates of 
40% to 95%, as defined by the degree of infiltration and the presence or not of ulceration. 
This means that sub-stage IIA is only considered of intermediate risk when it is ulcerated 
(Breslow 1.1-2 mm) or has a thickness of 2.1-4 mm without ulceration. High risk patients 
include sub-stage IIB (Breslow 2.1-4 mm ulcerated or > 4 mm non-ulcerated) and IIC 
(Breslow > 4 mm ulcerated). The variability of survival in these stages indicates its 
heterogeneity, and so other prognostic factors (mitotic rate, serum YKL-40, PTEN and Ki67 
expression, etc.) must be included to better discriminate different patient sub-groups (Liu et 
al. 2006, Schmidt et al. 2006, Mikhain et al. 2005, Gimotty et al. 2005). Stage III patients are 
also a very heterogeneous group, with high risk and worse prognosis as they always involve 
lymph node affectation where the number of affected nodes are an indicator of survival, 
age, location, and the presence of macro or micro metastasis in the lymphatic nodes (67% vs. 
43% up to 5 years, p<0.001) etc. also having an influence. (Tables 2 and 3) (Coit et al. 2006, 
11. Balch et al. 2010).  
In this stage and in the near future, other factors must be considered such as serum a protein 
S-100B level which is an independent prognostic factor as an initial baseline measurement 
but also during the follow up, different gene expressions, circulating melanoma cells, etc. 
They would provide information in addition to standard clinical and histological 
information, and bring about an improvement in the precision of both, the diagnosis and the 
prognosis. It will contribute, as already mentioned, to this therapeutic future (Suciu et al. 
2007, Mocellin et al. 2006, Fecher et al. 2007, Tarhini et al. 2009). 
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Factor   Value of "p" 
 
Patient age     <0.0001 
Male vs. female    0.12 
Primary location    0.002 
Ulceration of primary tumour     0.13 
Breslow thickness    0.05 
No. of positive nodes   <0.0001 
Clinical affectation of nodes    0.0003 
Micro vs. macro metástasis in the lymphatic nodes     <0.001 
Extranodal extension    0.07 
Table 2. Prognostic factors in stage III 
 
Low risk melanomas: 
 -Stage I. 
 
Intermediate risk melanomas: 
 -Stage II A (Breslow of 1.1- 2 mm Ulcerated) 
   (Breslow of 2.1- 4 mm Non-ulcerated). 
 
High risk melanomas: 
 -Stage IIB. (Breslow of 2.1- 4 mm Ulcerated) 
   (Breslow >4 mm Non-ulcerated) 
 
 -Stage IIC. (Breslow >4 mm Ulcerated). 
 -Stage III. 
Table 3. Melanomas: risk groups 
2. Adjuvant treatment 
The treatment of choice for localised primary cutaneous melanoma (stages I, II and III) is 
surgery and if there is regional affectation of the lymph nodes or if the sentinel lymph node 
is positive, this must be completed with lymphadenectomy. The resection should be deep in 
accordance to the thickness of the primary lesion. The recommended width of the margins 
should be 1 cm, for lesions 1 mm thick. In melanomas of 1-4 mm, about 2 cm is 
recommended and for lesions of more than 4 mm, about 3 cm. Elective regional 
lymphadenectomy is not recommended unless the study of the sentinel lymph node was 
positive. Up to 37% of these cases have nodes affected. Therapeutic lymphadenectomy 
should be performed when lymph nodes metastases have been clinically diagnosed. Surgery 
should be assessed once again for the metastatic disease, especially for metastases of the 
skin or those attached to organs, and they would be considering as candidates for adjuvant 
treatment. 
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The rationale of adjuvant treatment to surgery is based on the poor prognosis of high-risk 
melanomas, with a relapse rate of 50-80% and a low five-year survival of 25-70% (Moreno-
Nogueira, 2008). Another reason would be that metastatic disease has no efficient treatment 
capable of significantly prolonging patient survival. 
Patients included in the high-risk group should be assessed for adjuvant treatment with 
high doses of Interferon-α2b, as it is the only treatment shown to significantly improve 
disease free and possibly global survival.  
Different types of adjuvant treatment have been investigated and others are under study 
and pending results. 
2.1 Adjuvant treatment with chemotherapy 
In randomised studies, adjuvant chemotherapy has not shown any significant benefits, even 
at high doses with the support of autologous bone marrow. (Table 4) (Moschos and 
Kirkwood, 2005). 
 
Authors No. of
cases 
Stage Treatment Follow-up 
(years) 
Statistical 
significance 
Fisher  
1981 
181 II-III CCNU 
Observation 
3 y. NS 
Veronesi  
1982 
931 II-III DTIC 
BCG 
DTIC+BCG 
Observation 
5 y.  
NS 
Lejeune  
1988 
325 I-IIA-IIB DTIC 
Levamisole 
Placebo 
4 y.  
NS 
 
Meisenberg  
1993 
 39 III Autologous bone marrow transplant N.A. NS 
 
NA: Not announced. NS: Not significant. 
Table 4. Melanomas: Adjuvant chemotherapy. Randomised studies 
2.2 Adjuvant treatment with biochemotherapy 
Various studies, with contradictory results, have been published of combined treatment 
with chemotherapy and cytokines; nevertheless, this is an interesting line for further 
investigation. A first study with 138 patients, 71 treated with biochemotherapy (cisplatin + 
vinblastine + DTIC + IFN + IL2) compared to two treatments with high dose Interferon-α2b, 
(33 patients.) vs. intermediate doses (33 patients.), did not show any significant differences 
in the groups regarding GS and RFS (Kin et al. 2006). A second study compared two cycles 
of DTIC 850 mg/m2 followed by Interferon-α2b 3 mill./3 s.c., during six months, compared 
to observation in patients with stage IIa, IIb, IIIa and IIIb. There were no significant 
differences regarding RFS and GS in low risk patients (IIa), but the differences were 
significant in high risk patients with a RFS at 5 years of 42% vs. 17% (p=0.0018) and a GS at 7 
years of 51% vs. 30% (p=0.0077). The benefits were more evident in metastasis free survival 
and the procedure has an acceptable toxicity (Stadler and Luger, 2005). On the other hand, a 
wide Phase III study from DeCOG (Dermatologic Cooperative Oncology Group) with 441 
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patients with regional lymphatic clearance after having positive nodes compared: IFN α2a, 3 
MU s.c. three times a week (A), (A) plus DTIC 850 mg/m2 every 4-8 weeks for two years (B) 
and just observation (C). The results showed significant improvement in RFS and OS in 
group A vs. C, but with no differences between B and C, meaning possibly that DTIC 
reverts the benefits of adjuvant IFN (Garbe el al. 2008). 
There are also some studies of neoadjuvant treatment with biochemotherapy. One in Stage 
III with 48 patients analysed the association of cisplatin + vinblastine + DTIC + IFL + IL2. At 
five years the GS was 66% and the RFS was 56%, higher than historic controls (Lewis, 2006). 
2.3 Adjuvant treatment with immunostimulants 
Seven studies with non-specific immunostimulants did not show any significant benefits 
(Table 5) (Moschos and Kirkwood. 2005) 
 
Authors No. of cases Stage Treatment. Follow-up 
(years).  
Statistical 
significance 
Balch 1982 260 III C. parvum 2 y. NS 
Paterson 1984 199 I-II BCG 4 y. NS 
Miller 1988 168 II-III Transfer factor 
Observation 
2 y. NS 
Lipton 1991 262  C. parvum 
BCG 
4 – 9 y. CS 
Quirt 1991 577 I-IIA-IIB- Levamisole 
BCG 
BCG+Levamisole
Observation 
  
Spitler 1991 216 I-IIA-IIB-III-IV Levamisole 
Observation 
10 y. NS 
Czarnetzki 
1993 
353 ii BCG (RIV) 
BCG (Pasteur) 
Observation 
6 y. NS 
CS: Close to significance. NS: Not significant. 
Table 5. Melanomas. Adjuvant treatment with non-specific immune stimulants. Randomised 
studies 
2.4 Adjuvant treatment with vaccines 
Various vaccines against melanoma are currently under development, some of them in 
Phase I, II and III clinical trials, but in general they have not offered any advantages except 
in one study which only included 38 patients (Table 6) (Moschos and Kirkwood, 2005). 
Melacine, a vaccination made from cell lysate was compared to observation by SWOG 
(Southwest Oncology Group) in patients with melanoma of 1.5-4 mm in thickness without 
lymph node affectation. No benefit was observed but a retrospective analysis showed that 
the vaccinated patients that had positive HLA-A2 or C3 presented a disease free survival of 
77% compared to 64% of patients with the negative marker observed (Sosman et al. 2002). In 
the ECOG 1694 study, the group that received the vaccination of Ganglioside GM2 activator 
protein fared worse than the group with high doses of Interferon-α2b after a relatively short 
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Authors No. of cases Stage Treatment Follow-up 
(years.) 
Statistical 
significance 
Livingston 
1994 
123 III GM2+BCG+CFM 
BCG+CFM 
5 y. NS 
Wallack 1995 250 II Virus allogeneic 
polyvalent 
melanoma cell lysate
2.5 y. NS 
Wallack 1998 250 III Melanoma cell lysate 
vaccine 
3 y. NS 
Bystryn 2001 38 III Polyvalent shed 
antigen 
Placebo 
2.5 y. S 
Sondak 2002 689 IIA Melacine and 
DETOX 
Observation 
5.6 y. NS 
Hershey 700 IIB Cell lysate vaccine 
Placebo 
8 y. Tendency in 
RFS/GS 
Table 6. Melanomas. Adjuvant treatment with vaccines. Randomised studies 
 
 RFS DMFS OS 
 
OBS  
GM2- 
KLH/QS-21 
OBS  
GM2-
KLH/QS-21 
OBS  
GM2-
KLH/QS-21 
Nº events 204  205 143   52 112  124 
4-yr %(SE%) 69.4% (1.9%) 68.2%(1.9%) 78.8%(1.7%) 6.1%(1.8%) 83.6%(1.6%)  81.5%(1.6%) 
HR (95% CI)* 1.03 (0.84, 1.25) 1.11 (0.88, 1.40) 1.16 (0.90, 1.51) 
P value* 0.81 0.36 0.26 
Abbreviation: HR, hazard ratio. * Cox model, stratified for stratification factors. 
OBS: Observation. RFS: Relapse-free survival. DMFS: Distant metastasis-free survival.  
OS: Overall survival 
Table 7. Final results of study EORTC 18961 
median follow-up. However this study did not include a control group without adjuvant 
treatment, and so it is not possible to determine whether vaccination with ganglioside was 
equivalent to observation or even prejudicial (Kirkwood et al., 2001). A recently presented 
randomised trial, where 604 patients in stage III were enrolled between April 1997 and 
January 2003, studied vaccination of allogeneic melanoma lysates with low doses of 
Interferon α-2b, compared to high doses of Interferon α-2b. At five years there were no 
differences in GS (61% vs. 57%) or RFS (50% vs. 48%), between both groups, but these 
figures were better than those for patients who did not receive any adjuvant treatment. The 
incidence of important side effects was similar, but the neuropsychiatric toxicity was higher 
in the second group (Mitchell et al., 2007). The final results of the Phase III Study form 
EORTC 18961 have been presented in the ASCO 2010 meeting. The study had 1314 patients 
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in stage II (T3-T4N0M0), between March 2002 and December 2005, divided into two groups, 
the ones with GM2-KLH/QS-21 vaccination after surgery and the ones that were just 
observed. The study had to be stopped because it did not show good results as supposed 
and the vaccination could be potentially harmful to patients. (Table 7) (Eggermont et al, 
2010). 
2.5 Adjuvant treatment with interferon 
At present the most common adjuvant treatment in high risk melanomas is Interferon-α2b 
at high doses according to the Kirkwood scheme (Induction: Interferon-α2b: 20 million/m2, 
i.v., 5 days a week for four weeks. Maintenance: Interferon-α2b: 10 million/m2, s.c., three 
times a week for 48 weeks), which should also be assessed after metastasis surgery, without 
evidence of tumour. 
Interferon is a glycoprotein described in 1957 by A. Isaacs and J. Lindemann as a product of 
virus infected cells that interfered with the replication of live virus in cell cultures. In the 
eighties, cloning by genetic engineering of a human interferon gene in Escherichia coli, 
enabled the production of large amounts of interferon thus simplifying clinical research into 
cancer treatments. There are more than 20 varieties, but the three most important are 
Interferon α, ǃ, and Ǆ, all being used in clinical oncology, especially α. 
The genes that code interferon α and ǃ are found in chromosome 9, whereas the gene coding 
the Ǆ is in chromosome 12. Both α and ǃ are structurally similar, with the same number of 
amino acids, the homology of the sequence of nucleotides being 45% and 29% for amino 
acids. 
Interferon acts by binding to a specific membrane receptor protein, thus unleashing a 
cascade of signals whose end result is the expression of a certain number of genes. 
Interferon α and ǃ share the same receptor, but ǃ has greater affinity. The gene of this 
receptor has been found in chromosome 21 and for interferon Ǆ in chromosome 6 (Faltynek 
et al. 1986, Pestka, 1997). 
The proteins produced as a result of gene activation and expression, participate in different 
biological activities such as antiviral and immunomodulating actions, reduction of cell 
proliferation, suppression of gene expressions, inhibition of angiogenesis, induction of cell 
differentiation etc.  
Oncological pathology essentially uses Interferon α (IFNα-2a and IFNα-2b) as a single agent 
or in combination with chemotherapy or other cytokines and monoclonal antibodies. 
Interferon-α2b was the first to be produced using the DNA recombinant technique and 
approved by the United States FDA. Over the last 15 years numerous studies have been 
carried out in various neoplasias, including lymphomas, CML, melanomas and kidney 
cancer. 
The antineoplastic activity of interferon has a double mechanism, it inhibits the proliferation 
and growth of tumour cells, directly affecting all phases of the cell cycle (M, G1 and G2), 
prolonging the cell cycle and reducing the number of cells that enter phase S and G2. The 
accumulative effect of prolongation of the cell cycle has cytostatic action and increases 
apoptosis. In second place it acts indirectly by inducing an increase of the antigen 
expression of the Class I and II major histocompatibility complex on the surface of tumour 
cells, exercising an effect on modulation of the immune response to these cells. These 
antigens play an important role in recognition of neoplastic cells by cytotoxic T-cells 
together with increasing the effectiveness of all effector immune cells with cytotoxic capacity 
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(NK cells, macrophages etc.) on these tumour cells. The increased interferon induced 
expression of TNF-α receptors on the surface of these cells, and increases the cytostatic and 
cytotoxic action of TNF-α, whose production is also increased. Something similar also 
occurs with other cytokines (CSF, IL1 etc.) that are involved in immune antitumorigenic 
cytotoxicity mechanisms (Foss, 2002). 
Another effect of interferon is the inhibition of tumour angiogenesis. Systemic treatment 
with interferon α and ǃ reduces growth endothelial cells, essential for the formation of new 
vessels, by inhibition of angiogenic factors, thus having an indirect anti-proliferation effect. 
Interferon α reduces the expression of FGF-2 and the transcription of VEGF. This is further 
enhanced by another possible mechanism, inhibition of IL-8, which has neo-angiogenic 
capacity in numerous neoplasias. 
Interferon has been widely investigated in melanomas, both as adjuvant to locoregional 
treatment, as well as in the metastatic phase in the case of a tumour with evident 
immunogenic activity. 
The adjuvant treatment most recognised at present in high-risk melanomas specially in USA 
is Interferon-α2b at high doses and according to the Kirkwood scheme. This scheme has 
been used by the Eastern Cooperative Oncology Group and Intergroup to perform four 
randomised studies on 1916 patients whose data was updated in 2004 (Figure 1). 
 
Fig. 1. Eastern Cooperative Oncology Group and Intergroup IFN 
The first study, E1684, showed that patients who received adjuvant treatment presented a 
recurrence free survival (RFS) at five years of 37% compared to 26% (p=0.0023) in the 
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untreated group. The global survival at five years was also significantly better (46% vs. 37%, 
p=0.0237) and this information enabled approval of IFN-α 2b as adjuvant treatment in high 
risk melanomas by the United States FDA, as well as the Spanish Ministry of Health.  
When this study was updated with a median follow-up of 12.6 years, it maintained the 
benefits in RFS (HR=1.38, p=0.02). The benefits for GS descended slightly (HR=1.22, p=0.18), 
but this could be due to deaths by other causes in the elderly population of the study 
(current mean age of > 60 years). 
The second E1690 study also showed benefits in RFS after a follow-up of 6.6 years (HR= 
1.24; p2=0.09), but not for GS. 
In the combined analysis of these two ECOG studies with 713 patients and a median follow-
up of 7.2 years, high doses of Interferon-α2b were better than the observation group in 
regard to the RFS (HR= 1.30, p < 0.002). However this analysis showed no benefit in global 
survival (GS) (HR= 1.08, p=0.42). (Figure 2). 
 
 
Fig. 2. Joint analysis of the E1683 and E1690 studies recurrence free survival/global survival 
Study E1694 showed benefits in RFS and GS compared to GMK vaccine after a median 
follow-up of 2.1 years. Equally, study E2696 showed that the combination of GMK vaccine 
and Interferon-α2b at high doses reduced the risk of relapse compared to GMK alone 
(Figure 3) (Kirkwood et al. 2004). 
In view of the above, it is possible to say that in patients with resected high risk melanoma 
Interferon-α2b at high doses is an adjuvant treatment with clear evidence of increased RFS 
and moderate, but not significant, improvement of GS. Toxicity should be well assessed and 
explained to each patient, so that he/she participates in the decision making process. 
Adequate experience in the use of high dose interferon, with control of its toxicity and 
recommending good hydration, means that the majority of patients comply with the 
therapeutic plan and a relatively low number of dropouts. The most outstanding toxicity 
reactions are asthenia, neuropsychiatric symptoms, myelosuppression, alteration of liver 
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enzymes, etc. The neuropsychiatric effects may appear early or tardive and include signs of 
depression, anxiety and occasionally suicidal thoughts. (Table 8)  
 
 
Fig. 3. Studies E1694 and E2696. Recurrence free survival/global survival 
In conclusion, there are arguments in favour of the use of high dose Interferon-α2b as this 
treatment shows improvement of disease free survival in all studies carried out to date, and 
increased, but not statistically significant, global survival. The toxicity is undoubtedly high, 
but manageable in services with experience. Furthermore, there is no other therapeutic 
regimen that has shown benefits in adjuvant treatment of melanoma. However, there are 
also arguments against high dose Interferon-α2b. In the first place it is not clear which 
patient population really benefits from adjuvant treatment. The only clear benefit is for 
disease free survival; no consistent data is available for global survival. In second place the 
toxicity is considerable and requires a team with experience in its management even though 
a certain number of patients will abandon or suspend treatment for this reason. Finally the 
duration and ideal dosage for the treatment is unknown. (Table 9) (Jonasch and Haluska. 
2001, Trask et al. 2000). 
www.intechopen.com
 
Adjuvant Treatment of Melanoma 
 
129 
 Patients (%) * Patients (%) * 
Adverse effects All degrees Degree 3-4 
Asthenia 96 21-24 
Fever 81 18 
Myalgia 754 4-17 
Nauseas 66 5-9 
Vomiting 66 5 
Myelosuppression 92 26-60 
Elevated AST 63 14-29 
Neuropsychiatric symptoms 40 2-10 
 
- Depression. 
- Anxiety                             0-70% 
- Suicidal thoughts 
 
* Data taken from the E1684 study of 143 patients. ** Data taken from the E1684, E1690 
and E1694 studies. 
 
Table 8. Most common adverse events (degree III/IV) in patients treated with high dose 
IFN-α2b  
 
1) ARGUMENTS IN FAVOUR. 
 
• A consistent improvement in disease free survival has been demonstrated  
• in all studies carried out. 
• An improvement in global survival has been shown, but without this being 
statistically significant. 
• The toxicity is high, but manageable by experienced medical teams.  
• No other therapeutic regime has shown benefits in the adjuvance of melanoma. 
 
2) ARGUMENTS AGAINST. 
 
• It is not clear which population most benefits from the adjuvant treatment. 
• The benefit is only clear for disease free survival, there being no consistent 
information referring to global survival. 
• The toxicity is considerable. 
• The ideal duration and dose for the treatment are unknown 
 
Table 9. Arguments for and against high dose interferon as adjuvant treatment 
Other favourable arguments are the data from a study that analysed the quality adjusted 
survival (QAS) using clinical data from the E1684 and E1690 studies which pointed out that 
the majority of patients showed improvement of the QAS, but the benefit was only 
significant in 16% of patients in the E1684 study (Kilbridge et al. 2002).  
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A cost-effectiveness analysis of high dose Interferon-α2b as adjuvant treatment for high-risk 
melanomas in Spain, shows that it is within established limits for healthcare economy 
regarding the use of a new treatment (Gonzalez-Larriba et al. 2002). Another recent study of 
cost effectiveness in node positive melanomas shows, that the treatment was cost effective, 
even though it varied according to the sub-stage, and also highly effective in terms of 
quality of life per year in patients under 60 years of age with stage IIIC melanoma (Cormier 
et al. 2007). 
Even more recently a Stage III study was published comparing i.v. induction of Interferon 
α2b to the classic high dose scheme with induction and maintenance. At 51 months of 
follow-up, the RFS was 32 months vs. 31 months (p=0.836) and the GS was 61 months vs. 
63 months (p=0.444), without being significant differences. There were more dropouts in 
the classic treatment (p<0.001), mainly because of its duration and signs of recurrence 
more than for toxicity. This study, which included 355 patients, attempted to show the 
value of induction (no differences between both groups), but lacked on untreated control 
group, could not confirm this in a more evident way. However, the existence of this group 
was not considered after the information published on the benefits of adjuvance (Gogas et 
al. 2007).  
Another similar study presented in ASCO 2010 showed that patients in stage IIB and IIIA 
have similar RFS and OS in both groups, the ones with induction plus 8 weeks of 
maintenance dose and the ones with high doses according to Kirkwood regime (Sullivan et 
al. 2010). In high risk melanomas there is another study in Phase III with 364 patients that 
compares 4 weeks of induction versus 1 year of treatment with classic high doses of IFN, 
showing no significant differences in RFS and OS between both regimens (Pectasides et al. 
2009). There is also another Phase III randomized study from DeCIG MM-ADJ-5 with 380 
patients in stage III that compares 3 treatments with IFN α2b 20 MU/m2 i.v, five days a 
week for four weeks every four months and the classic regimen of high doses of IFN from 
Kirkwook, showing no significant differences in DMFS, but with better tolerance and safety 
with the intermitent treatment (Mohr et al. 2008). Therefore shorter regimens might 
encourage the use of IFN as an adjuvant treatment in melanoma patients. 
As a final summary it can be said that in patients with high risk resected melanoma, high 
dose interferon is the adjuvant treatment to be proposed, together with background 
information on its collateral effects, as there is clear and significant evidence of 
improvement in the RFS and moderate, although not significant improvement of the GS. 
New data have recently been published on high dose Interferon-α2b according to the 
Kirkwood scheme as neoadjuvant treatment prior to lymphadenectomy, in patients with 
palpable stage IIIB and IIIC adenopathies. After four weeks of intravenous phase among the 
20 patients enrolled, 11 (55%) showed response, three of them (15%) pathological complete 
response. At a median of 18.5 months follow-up, 10 patients continued disease free. In 
responding patients, cells CD11+ and CD3+ increased on the tumour and CD83+ decreased, 
indicating a correlation between reactivity of the immune system and the benefit of the 
treatment. This study also included molecular analysis with activation of STAT3 being 
observed and related to cell proliferation, high dose Interferon-α2b would reduce this 
protein and increase STAT1. This enables opening a new approach to adjuvant treatment in 
high risk patients which should be more widely explored (Moschos et al. 2006). 
Low and intermediate doses have not shown any real benefits in the adjuvant treatment of 
high-risk melanomas (Table 10) (Eggermont et al. 2005).  
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Trial No. of cases  SLE OS 
Low dose IFN (3 mU x 3/s x 3 y.): 
-WHO-16 (2001) 
-UK (2004) 
-Scottish study (2001) 
 
426 
674 
59 
 
NS 
NS 
NS 
 
NS 
NS 
NS 
Ultra-low dose IFN (1 mU): 
-EORTC/DKG-80 (2001) 
 
830 
 
NS 
 
NS 
Low dose INF + Isotretinoin (IFN: 3 mU x 3/s x 2 y.) 
-ECAMTSG (2005) 
 
407 
 
NS 
 
NS 
Intermediate dose IFN. 
-EORTC 18952 
 (10 mill. 13 m vs 5 mill. 25 m. vs observation) 
 
1388 
 
NS 
 
NS 
Table 10. High risk melanomas: adjuvant treatment with low and intermediate dose 
interferon 
But in the review by A. Verma et al. (2007),patients with high risk melanomas, the results 
show, that treatment with high doses of IFN constantly improve the SLR and the mortality 
rate at two years (p<0.03). The authors conclusion is that IFN at high doses is a reasonable 
option in selected patients. A recent meta-analysis evaluating 6067 patients from 10 trials 
found significant benefits in RFS and GS (p=0.00006 and p=0.008), even though the absolute 
benefits on survival are small, just a 3% at five years. This meta-analysis did not clarify the 
ideal dose of interferon neither the duration of the treatment and found a sub-group where 
the benefits were greater, the presence of ulceration in the primary tumour, but this needs 
clarification. (Wheatley et al. 2007).  
A recent Phase III randomized study from DeCOG, has compared low doses of IFN α2b 
(3MU three times a week) for 18 months (group A) versus 60 months (group B), in patients 
with primary melanoma, a Breslow’s thickness ≥ 1.5 mm and negative lymphadenopathies 
clinically. The 75.6% of them had a sentinel lymph node biopsy, with a positive results in 
18% in the group A and 17.5% in the group B. Overall they had 840 patients, with a median 
follow up of 4.3 years, and it did not show any benefits with prolonged treatments. All this 
suggest that the optimal length of the treatment with IFN is still nuclear (Hauschild et al. 
2010). 
It has been published recently some data on adjuvant treatment with pegylated Interferon 
α2b (PEG-IFN) from the EORTC 18991 study (Induction of 6 μg/Kg/week, s.c. for 8 weeks, 
followed by maintenance at the dose of 3 μg/Kg/week, s.c., for a total duration of 5 years). 
The study included 1256 patients in stage III (any T, N1-2, Mo, without metastasis in transit). 
Patients were randomised into two groups, one for treatment (608 p.) and the other for 
observation as a control (613 p.). The randomization was divided into positive microscopic 
lymphadenopathy (N1) versus macroscopic one (N2), number of positive lymph nodes, 
tumour ulceration and Breslow’s thickness, sex of the patients and the referral center, 
analysing the data according to the intention to treat. The average length of treatment with 
PEG-IFN was 12 months (IQR: 3.8-33.4). The mean follow up was 3.8 years, and 328 
recurrences were observed in the interferon group vs. 368 in the control one (p=0.01), being 
at four years the RFS value 45.6% in the first group and 38.95 in the second one, showing a 
risk reduction of 18% (p=0.01). No significant differences were observed between the two 
groups in OS. Grade 3 adverse event occurred in 246 (40%) patients in the interferon group 
and 80(10%) in the observation group; grade 4 adverse events occurred in 32 (5%) patients in 
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interferon group and 14 (2%) in the observation group. In the interferon group the most 
common grade 3 or 4 adverse events were fatigue (97 patients, 16%), hepatotoxicity (66 
patients, 11%), and depression (39 patients, 6%). Treatment with PEG-IFN was discontinued 
because of toxicity in 191(31%) patients. Regarding the quality of life, there was a negative 
effect in the group treated with IFN with a decrease in social activity and appetite. Knowing 
that PEG-IFN increases the RFS, the patients should be informed about the negative effects 
of the treatment and they should be encourage to participate in the planning of it (Table 11). 
(Eggermont et al., 2008; Bottomley et al., 2009).  
 
 RFS DMFS OS 
 Obs. PEG-IFN Obs. PEG-IFN Obs. PEG-IFN 
No. of events 368 328 325 304 263 262 
Rates at 4 years   39% 46% 45% 48% 56% 57% 
Mean years   2.1 2.9 3.0 3.8 NR NR 
HR (95% CI)   0.82 
(0.71-0.96) 
0.88 
(0.75-1.03) 
0.98 
(0.82-1.16) 
Value of "p”   0.01 0.11 0.78 
Table 11. Pegylated interferon. Results of the EORTC 18991 study 
 The EADO trial is a Phase III study with excised melanomas ≥ 1.5 mm of thickness and no 
affected lymph nodes clinically. Patients were randomized to received IFNα-2b (3 MU 
subcutaneously three times a week for 18 months) versus PEG-IFN (100 mcg. 
Subcutaneously once a week for 36 months). Out of 898 patients included, 896 were 
evaluated (453 IFN and 443 PEG) with a mean follow up of 4.7 years. Sentinel node biopsy 
was performed in 68.2% because it was not a standard procedure initially. The recurrence 
free survival (RFS) was 64.8% vs. 66.2% (p=0.43), the distant metastasis free survival (DMFS) 
was 72.6% vs. 71.3% (p=0.55), not showing significant differences. Adverse effects of grade 
3-4 were seen in 26.6% vs. 44.6% in the first 18 months, which affected the mead length of 
treatment (17.8 months vs. 19.2 months, completing the full 36 months of treatment 28% of 
the patients). In summary, low doses of PEG-IFN was no better than low doses of 
conventional IFNα-2b. Trying to increase the benefits of PG-IFN by increasing the length of 
the treatment up to three years is not easy, because the high numbers of patients not 
completing the full treatment due to the side effects is important and therefore would not 
solve the clinical needs of them (Grob et al. 2010). Advocating the use of IFN in melanomas, 
a new meta-analysis has recently been published with a large number of patients reviewing 
the adjuvant treatment with IFN-α in high risk cases, in relation to DFS and OS, and also it 
has been studied the effect of the doses and the length of the treatment. There were 14 
randomized studies included between 1990 and 2008, with a total of 8122 patients, out of 
which 4362 were treated only with IFN-α, the rest were only observed. The treatment with 
IFN-α is associated to and improvement of the DFS (p< 0.001/ 18% risk reduction) and also 
of the SG (p=0.002/ 11% risk reduction) (Figures 4 and 5).  
The study has its own limitations according to the authors and therefore it cannot 
recommend the regime, doses or length of the treatment, neither, which subgroup of 
patients would respond better the adjuvant therapy. Given the lack of and effective systemic 
treatment to treat the melanoma, the meta-analysis suggests the use of IFN-α on the daily 
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clinical bases to offer the patients the best survival opportunities. It is important to 
remember that other adjuvant therapies well established for other types of cancer like 
breast, colorectal and ovarian is associated with a risk reduction. These data suggest that it is 
very important to research the molecular mechanism that could explain the sensibility to the 
IFN-α to try to identify the group of patients that would benefit most from it (Mocellin et al. 
2010). 
 
 
HR: Hazard ratio. LL: Lower limit. UL: Upper limit. SE: Significant estimate. 
Fig. 4. Meta-analysis. Disease-free survival 
 
 
HR: Hazard ratio. LL: Lower limit.  UL: Upper limit.  
Fig. 5. Meta-analysis. Overall survival 
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Given the characteristics of adjuvant treatment with Interferon-α2b, it would be extremely 
important to find factors predicting efficiency and parameters for classification of patients to 
enable a better choice of therapy. Autoimmunity seems to be a factor predicting efficiency in 
adjuvant treatment with interferon. A prospective study with high dose interferon analysed 
the autoimmune response through the appearance of thyroid, anticardiolipins, antinuclear, 
antiDNA autoantibodies or the presence of depigmentation. A quarter of all patients treated 
develop autoimmunity phenomena. After a follow-up of 45.6 months, only 13% of those 
presenting autoimmunity had suffered relapse and 4% had died. In the group that 
presented no autoimmunity reactions, 73% suffered relapse and 54% died. The mean 
survival has not been reached among the patients with autoimmunity phenomena and was 
37.6 months in the group without these manifestations. Therefore, after multivariate 
analysis, autoimmunity constitutes a significant predictive factor for global and disease free 
survival (Gogas et al. 2006). 
On the other hand, the trial 18991 from EORTC where adjuvant IFN was compared versus 
control, the presence or not of autoantibodies (anti-cardiolipin, anti-thyreoglobulin y 
antinuclear) did not represent an important prognostic factor and did not find a significant 
relationship with the treatment (Bouwhuis et al. 2010). 
The determination of HLA is also a factor predicting recurrence in patients treated with 
Interferon α2b as adjuvant treatment. The percentage of relapse is significantly lower in 
patients with HLA genotype A33, HLA B57, HLA-Cw03 and HLA-Cw06. (Gogas et al. 
2006). 
It therefore seems essential to be able to discriminate those patients who would really benefit 
from adjuvant treatment with Interferon α2b, thus avoiding all side effects in patients that 
would not really benefit. In addition, this would also have a considerable economic impact. 
2.6 Adjuvant treatment with GM-CSF 
The GM-CSF is an important hematopoyetic growth factor, codified by a gene placed in the 
long arm of chromosome 5 (5q21-q32), present in monocytes, fibroblasts and endothelial 
cells, with an stimulating action over the developing and maturation of stem cells that will 
become neutrophils, eosinophils monocytes and macrophages. Is has been use 
therapeutically to treat QT induced neutopenias. The in-vivo studies have shown that 
recombinant GM-CSF increases the citotoxic activity of monocytes and lymphocytes, and 
also increases the activity of macrophages by increasing the production of matrix 
metaloprotheasas and angiogenesis inhibitors, and therefore an overall anti-tumoral effect, 
together with the increased inmunogenicicy of the tumoral cell, facilitating the antigen 
presentation. The reason for its use as an adjuvant therapy in excised high risk melanoma is 
because it also induces dentritic cell differentiation. In 2000 the first results were published 
on GM-CSF showing benefits on survival in relation to historic controls in stage III patients 
with a poor prognosis or stage IV with resected disease. Recent data on 98, high risk patients 
under treatment for three years, show a mean survival of 58.7 months, longer than the result 
of 37.5 months obtained in the first study where treatment only lasted one year. The benefits 
were especially observed in stage IIIc. The conclusion was the superiority of long-term 
treatment over three years, especially in patients that maintained eosinophilia for a longer 
period of time. 
This study has been reviewed recently and once again they conclude that GM-CSF for three 
years increases the survival in patients with a high recurrent risk of melanoma (HR = 0,61;  
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p = 0,047), but those on three years treatment have potentially causing AML, as it did 
happened in two patients. Immunological studies showed an increase of neopterin related 
to the macrophages activity that potentially could explain the mechanism of action of the 
therapy (Spitler et al. 2008). The Phase III study E4697 that compares GM-CSF versus 
placebo as an adjuvant treatment in staging III-IV melanoma that were excised, did included 
815 patients (1999 to 2006), out of which 735 were eligibles. The overall mean survival rate 
was 72.1 vs. 59.8 months (p = 0.551) and the disease free survival was 11.8 vs. 8.8 months  
(p-0.034), with a minimum toxicity (Lawson et al. 2010). Undoubtedly the use of GM-CSF as 
monotherapy or in combination in adjuvance is a line of research that must be confirmed 
over the next few years. 
2.7 Adjuvant radiotherapy 
It is an option in melanomas with a high risk of regional recurrence after lymphatic 
clearance, specially in those cases with extra lymphatic extension, a positive lymph node 
greater than 3 cm, 4 or more positive nodes, residual disease or a Breslow’s thickness equal 
or greater that 4mm. In a randomized study with 227 patients considered as having high 
risk of recurrence, 109 were included in the adjuvant radiotherapy group and 108 on the 
control group. After a mean follow up of 27 months, 20 patients had a recurrence in the 
radiotherapy group and 34 in the control one (p=0.0410), indicating a better control of the 
local recurrence with radiotherapy but not affecting the survival rate (Henderson et al. 
2009). 
3. New treatments  
The lack of proven efficient treatments against metastatic melanoma affects the use of the 
adjuvant treatment. Chemotherapy, cytoquines, vaccines and combination treatments have 
been studied with little success. Only IFN has shown to be beneficial in DFS and in less 
degree in OS in high risk patients, therefore it is necessary to continue to research for new 
therapies. A new line of research has been found in the monoclonal auto-antibodies anti-
CTLA-4 that block the interaction between B7 (B7-1 and B7-2 are homologous costimulatory 
ligands expressed on the surface of antigen presenting cells) and CTLA-4 (Cytotoxic  
T-Lymphocyte Antigen 4), causing a negative inhibition that increases the citotoxicity of  
T-lymphocytes with antitumoral activity (Eggermond et al. 2010). At present, there are  
two monoclonal antibodies on phase II/III trials, use on their own or in combination: 
Ipilimumab and Tremelimumab. 
Early-phase (I/II) clinical studies of tremelimumab demonstrated acceptable toxicity, mostly 
immune-related adverse events and similar efficacy of 10 mg/kg monthly and 15 mg/kg 
quarterly doses of the antibody with median survival times of 10.3 and 11 months, 
respectively. Both phase II regimens generated durable tumor response (Camacho et al. 
2009). 
Interesting data were presented at the 2010 annual meeting of the ASCO (American Society 
of Clinical Oncology), regarding the combination of Tremelimumab and HDI (High-dose 
Interferon alpha-2b) in a phase II trial in patients with metastatic melanoma. With an overall 
response rate of 30%, a progression-free survival rate at 6 months of 53%, and a median OS 
of 15.9 months, the results were very encouraging, especially since there seemed to be no 
added toxicity associated with the combination de Tremelimumab and HDI. Autoimmunity 
induced by therapy is significantly correlated with therapeutic benefit (Tarhini et al. 2010). 
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There are several studies in the last few years about metastatic melanoma and Ipilimumab 
as the only treatment and in combination with DTIC with survival rates of 11.5 and 13 
months respectively. The presence of autoimmune reactions (diarrhoea, colitis and 
dermatitis) that can be controlled with steroids, can be used as a marker to asses the respond 
and duration of the treatment. A phase III study compares monotherapy with Ipilimumab 
and placebo (137 p.) versus Ipilimumab and vaccine gp100 (403 P.) versus placebo and 
vaccine gp100 (136 p.) in patients with stage III melanoma not excised or stage IV previously 
treated, with the main aim on the overall survival rate (OS). The mean survival was 10.0 
months for the group that had Ipilimumab and gp100 and 6.4 months for the group that had 
gp100 alone (p=0.001). The survival of the patients who only had Ipilimumab was 10.1, also 
better that the gp100 alone group (p=0.003), not showing any differences between the 
groups with Ipilimumab. Immune reactions grade 3-4 were seen in about 10-155 of patients 
treated with Ipilimumab and 7 deaths were related to these side effects. In summary, 
Ipilimumab is the first drug that increases the survival in patients with advanced melanoma 
previously treated (Hodi et al. 2010). 
The lack of benefit observed in stage IIIB/C with adjuvant IFN therapy was, for the EORTC 
Melanoma Group, the reason to move to a different drug. Thus, the EORTC 18071 pivotal 
adjuvant trial in stage IIIB/C, comparing a 3-years treatment with Ipilimumab to placebo in 
a double-blind randomized setting, was activated in 2009 and is expected to be completed in 
2011. 
4. Final comments 
The reality is that except for data on IFN, no new validated strategies that improve results 
have come to the fore. The unquestionable increase of our understanding of the cell biology 
of melanomas leads to the idea of identification of sub-groups where the benefits would be 
greater. It is therefore absolutely necessary to identify new therapeutic targets, develop new 
drugs and make an optimal selection of patients. One of the most interesting targets is the 
analysis of the BRAF gene, mutated in 50-70% of melanomas, and furthermore associated 
with exposure to ultraviolet light. This mutation gives rise to a protein with a kinase activity 
about 500 times higher than the un-mutated protein thus enabling greater survival and 
proliferation of neoplastic cells. Sorafenib, a double target anti-angiogenic which inhibits 
BRAF on the one hand and VEGFR and PDGFR on the other, in association with CDDP in 
metastatic melanomas results in 13% PR and 53% SD. PD0325901 is another important 
inhibitor of the BRAF signal cascade (MEK1 and MEK2) and its efficiency has been tested in 
preclinical models as well as PLX40323 (Solid and Rosen, 2011). Nevertheless, the use of 
CTLA-4 inhibitors such as Ipilimumab and Tremelimumab, open new horizons in the 
treatment of melanomas and the future studies about adjuvant therapies, can change the 
prognosis, specially in high risk patients. 
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